Updates to HER2CLIMB in HER2+ MBC
November 29th 2021Breast oncologists react to updated overall survival data, progression-free survival data, and quality-of-life data from the HER2CLIMB study of tucatinib for HER2+ metastatic breast cancer, as well as consider using the drug in combination with other novel therapies.
Read More
HER2+ Breast Cancer: Key Takeaways From HER2CLIMB
September 8th 2021An overview of the latest data demonstrated by the HER2CLIMB study evaluating the efficacy and safety of tucatinib in combination with capecitabine and trastuzumab for patients with relapsed/refractory metastatic HER2-positive breast cancer.
Read More
Standard of Care for R/R Metastatic HER2+ Breast Cancer
September 8th 2021Current treatment options and outcomes for patients with metastatic HER2-positive breast cancer who progress on HER2-targeted therapy, with special insight regarding the management of brain metastasis and visceral disease.
Read More